» Articles » PMID: 29990546

Tricyclic Antidepressants Inhibit Candida Albicans Growth and Biofilm Formation

Overview
Date 2018 Jul 11
PMID 29990546
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Candida albicans is a commensal yeast of the human body, able to form biofilms on solid surfaces such as implanted medical devices, and contributes to nosocomial infections. Biofilms have the capacity to resist higher levels of antifungals compared with planktonic cells, and can develop tolerance to commonly used treatments. The necessity to overcome acquired drug resistance and identify new active molecules with low toxicity is a significant problem. It has been reported that some antidepressants have antibacterial properties, but little is known regarding the effect of these drugs on fungi. This study demonstrated the capacity of three tricyclic antidepressants (doxepin, imipramine and nortriptyline) to inhibit the growth and biofilm formation of Candida spp. The antimicrobial potential of the drugs was assessed by studying gene expression, hyphae formation, biofilm growth and maturation. Their negative impact on the growth of C. albicans and other Candida spp. is shown in vitro and with the hepatic S9 system, which is preliminary to any in-vivo test. This study found that the antidepressants considered can inhibit not only hyphae and biofilm formation, but also kill cells in a mature biofilm. Moreover, cell lysis by nortriptyline was observed, along with its synergistic activity with amphotericin B. These findings suggest that tricyclic antidepressants, particularly nortriptyline, should be studied further in drug repositioning programmes to assess their antimycotic capacity in full.

Citing Articles

Heterocyclic Antidepressants with Antimicrobial and Fungicide Activity.

Zolotareva D, Zazybin A, Belyankova Y, Bayazit S, Dauletbakov A, Seilkhanov T Molecules. 2025; 30(5).

PMID: 40076325 PMC: 11902072. DOI: 10.3390/molecules30051102.


Exploring the Antibiofilm Effect of Sertraline in Synergy with Essential Oil to Counteract Species.

Barbarossa A, Rosato A, Carrieri A, Fumarola L, Tardugno R, Corbo F Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338275 PMC: 11435152. DOI: 10.3390/ph17091109.


Analysis of the anti-Candida activity of tricyclic antidepressants in association with amphotericin B and their antifungal mechanisms.

de Farias Cabral V, Rodrigues D, Sa L, Moreira L, da Silva C, de Andrade Neto J Braz J Microbiol. 2024; 55(4):3617-3628.

PMID: 39198376 PMC: 11711746. DOI: 10.1007/s42770-024-01459-y.


Pharmacomicrobiomics and Drug-Infection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy.

Torres-Carrillo N, Martinez-Lopez E, Torres-Carrillo N, Lopez-Quintero A, Moreno-Ortiz J, Gonzalez-Mercado A Int J Mol Sci. 2023; 24(23).

PMID: 38069427 PMC: 10707377. DOI: 10.3390/ijms242317100.


Repurposing a human acetyl-CoA carboxylase inhibitor firsocostat to treat fungal candidiasis alone and in combination.

Chen T, Yao J, Quan K, Xu J, Hang X, Tong Q Antimicrob Agents Chemother. 2023; 68(1):e0113123.

PMID: 38018962 PMC: 10777831. DOI: 10.1128/aac.01131-23.